RGX-111

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

REGENXBIO faces class action lawsuit alleging securities violations over failure to disclose adverse information about RGX-111 before FDA clinical hold.

REGENXBIO faces securities fraud lawsuit for allegedly making false statements about RGX-111 safety while withholding adverse trial data from investors between February 2022 and January 2026.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.

Law firm sues REGENXBIO for allegedly hiding safety concerns about gene therapy RGX-111. Stock dropped 17.8% after FDA clinical hold due to tumor in trial participant.